Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the polymorphic forms I, II, and III of finasteride can be prepared purely, with form III being identical to what was previously referred to as form X.

In this study, 4-substituted N-(1,1-dimethylethyl)-3-oxo-4-androstene-17.beta.-carboxamides were synthesized and evaluated in vitro as potential 5 alpha-reductase inhibitors and antiandrogens.

This study found that LY320236 is a competitive inhibitor of type I and a non-competitive inhibitor of type II steroid 5alpha-reductase, indicating its potential as a dual inhibitor with differing modes of activity.

Reduced androgens linked to kinky hair disorder and hair loss; 5a-reductase inhibitors may help.

This review discusses the use of finasteride and alpha antagonists for symptomatic benign prostatic hypertrophy and suggests current studies are evaluating combination therapies as potential non-surgical alternatives.

This study suggests that inhibitors of steroidogenic enzymes may have therapeutic potential for certain behavioral disorders linked to dopaminergic hyperfunction, despite concerns about their endocrine impacts.

Finasteride's polymorphic form affects capsule quality and drug effect, requiring strict control.

This study observed that finasteride, especially when combined with electrolysis, effectively reduced hair growth in women with hirsutism over six months.

In this study, researchers found that finasteride exhibits a solid-solid phase relationship that is enantiotropic at normal pressure and becomes monotropic at higher pressure.

This article proposes a novel hypothesis that androgenetic alopecia may be mainly caused by skull bone expansion affecting blood supply to hair follicles rather than differences in individual follicle programming, and calls for more genetic research into skull development.

Proscar (finasteride) blocks 5α-reductase in sea urchin ovaries and testes, suggesting potential treatment for androgen-related conditions.

This review discusses hormonal manipulation for conditions like prostatic disorders and skin issues and highlights promising treatments like casodex and finasteride, but it reports no new clinical results.

This review summarizes the structural and chemical characteristics of current and novel antiandrogenic drugs but reports no new clinical findings.

MK-386 and finasteride together effectively reduce DHT levels, potentially treating acne and male pattern baldness.

This study found that certain steroidal compounds, especially 10a–10c, demonstrated strong antiandrogenic activity by binding to the androgen receptor and reducing prostate weight in a hamster model.

This study found that novel compounds moderately inhibited 5α-reductase type 1 activity compared to finasteride, offering valuable data on structure-activity relationships.

In this study, researchers developed a sensitive assay to measure the inhibition of steroid 5-α reductase (5AR) by chemicals like finasteride and dutasteride, revealing species-specific differences in inhibitor efficacy between human and fish cell lines.

This article discusses the various roles of steroids in vertebrate organ systems and notes several glucocorticoids that were among the Top 200 Drugs by sales in the 2010s, but it reports no new clinical findings.

This study established that a human epidermal model can be utilized to assess 5alpha-reductase activity and evaluate enzyme modulators, such as finasteride, for dermatological applications.

This study designed a novel model for 5a-reductase enzyme inhibitors using pharmacophore and 3D QSAR techniques, potentially allowing for improved prediction and development of drug therapies targeting benign prostatic hyperplasia.

This study found that solid-state NMR combined with X-ray techniques provided critical insights into the structure and solvation of finasteride polymorphs, identifying gaps in existing patent characterizations.

This review discusses U.S. patents in organic process development published in July and August 2004 and reports no new experimental results.

This review discusses the role of steroid 5 alpha reductase 2 in converting testosterone to DHT and its association with conditions like benign prostatic hyperplasia and prostate cancer; it reports no new results.

This article reviews the role and controversies of 5α-reductase inhibitors like finasteride and dutasteride in managing prostate cancer, without presenting new research results.

This article reviews the synthesis and properties of isotretinoin, tazarotene, minoxidil, and finasteride, and reports no new findings.

This study developed and validated an HPLC method to quantify impurities in finasteride, demonstrating its suitability for quality assurance of the drug and its related substances.

This article discusses the treatment of androgenetic alopecia and alopecia areata with finasteride and minoxidil but reports no new clinical results.

In this study, finasteride 1 mg/day for 12 months did not improve hair growth or slow hair thinning in postmenopausal women with androgenetic alopecia compared to placebo.

This review explores finasteride's effects on neuroactive steroid levels and their potential influence on disorders like depression and alcohol withdrawal but reports no new clinical findings.

This study explains finasteride's high potency and specificity as a mechanism-based inhibitor for treating benign prostatic hyperplasia by detailing its interaction with human type 2 steroid 5α-reductase.